Drug Screening Services

About HUB Organoids

HUB Organoids leverages its patented, IP-protected technology to generate physiologically relevant organoids from adult stem cells (Lgr5+) for preclinical and clinical drug testing. The company operates primarily as a service provider and technology licensor, offering drug screening, custom assay development, and its flagship 'Clinical Trial in a Dish' co-clinical testing platform. Its recent acquisition by the Life Science business of Merck KGaA, Darmstadt, Germany, provides significant resources and validation, positioning it to expand its impact across oncology, immuno-oncology, inflammatory diseases, and other therapeutic areas.

Therapeutic Areas